Mycophenolate mofetil versus azathioprine in kidney transplant recipients on steroid-free, low-dose cyclosporine immunosuppression (ATHENA) : A pragmatic randomized trial
BACKGROUND: We compared protection of mycophenolate mofetil (MMF) and azathioprine (AZA) against acute cellular rejection (ACR) and chronic allograft nephropathy (CAN) in kidney transplant recipients on steroid-free, low-dose cyclosporine (CsA) microemulsion maintenance immunosuppression.
METHODS AND FINDINGS: ATHENA, a pragmatic, prospective, multicenter trial conducted by 6 Italian transplant centers, compared the outcomes of 233 consenting recipients of a first deceased donor kidney transplant induced with low-dose thymoglobulin and basiliximab and randomized to MMF (750 mg twice/day, n = 119) or AZA (75 to 125 mg/day, n = 114) added-on maintenance low-dose CsA microemulsion and 1-week steroid. In patients without acute clinical or subclinical rejections, CsA dose was progressively halved. Primary endpoint was biopsy-proven CAN. Analysis was by intention to treat. Participants were included between June 2007 and July 2012 and followed up to August 2016. Between-group donor and recipient characteristics, donor/recipient mismatches, and follow-up CsA blood levels were similar. During a median (interquartile range (IQR)) follow-up of 47.7 (44.2 to 48.9) months, 29 of 87 biopsied patients on MMF (33.3%) versus 31 of 88 on AZA (35.2%) developed CAN (hazard ratio (HR) [95% confidence interval (CI)]: 1.147 (0.691 to 1.904, p = 0.595). Twenty and 21 patients on MMF versus 34 and 14 on AZA had clinical [HR (95% CI): 0.58 (0.34 to 1.02); p = 0.057) or biopsy-proven subclinical [HR (95% CI): 1.49 (0.76 to 2.92); p = 0.249] ACR, respectively. Combined events [HR (95% CI): 0.85 (0.56 to 1.29); p = 0.438], patient and graft survival, delayed graft function (DGF), 3-year glomerular filtration rate (GFR) [53.8 (40.6;65.7) versus 49.8 (36.8;62.5) mL/min/1.73 m2, p = 0.50], and adverse events (AEs) were not significantly different between groups. Chronicity scores other than CAN predict long-term graft outcome. Study limitations include small sample size and unblinded design.
CONCLUSIONS: In this study, we found that in deceased donor kidney transplant recipients on low-dose CsA and no steroids, MMF had no significant benefits over AZA. This finding suggests that AZA, due to its lower costs, could safely replace MMF in combination with minimized immunosuppression.
TRIAL REGISTRATION: ClinicalTrials.gov NCT00494741; EUDRACT 2006-005604-14.
Errataetall: |
CommentIn: Transpl Int. 2021 Nov;34(11):2001-2003. - PMID 34612545 |
---|---|
Medienart: |
E-Artikel |
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
---|---|
Enthalten in: |
PLoS medicine - 18(2021), 6 vom: 25. Juni, Seite e1003668 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Ruggenenti, Piero [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 04.10.2021 Date Revised 10.12.2021 published: Electronic-eCollection ClinicalTrials.gov: NCT00494741 EudraCT: 2006-005604-14 CommentIn: Transpl Int. 2021 Nov;34(11):2001-2003. - PMID 34612545 Citation Status MEDLINE |
---|
doi: |
10.1371/journal.pmed.1003668 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM327135735 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM327135735 | ||
003 | DE-627 | ||
005 | 20231225200115.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1371/journal.pmed.1003668 |2 doi | |
028 | 5 | 2 | |a pubmed24n1090.xml |
035 | |a (DE-627)NLM327135735 | ||
035 | |a (NLM)34166370 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Ruggenenti, Piero |e verfasserin |4 aut | |
245 | 1 | 0 | |a Mycophenolate mofetil versus azathioprine in kidney transplant recipients on steroid-free, low-dose cyclosporine immunosuppression (ATHENA) |b A pragmatic randomized trial |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 04.10.2021 | ||
500 | |a Date Revised 10.12.2021 | ||
500 | |a published: Electronic-eCollection | ||
500 | |a ClinicalTrials.gov: NCT00494741 | ||
500 | |a EudraCT: 2006-005604-14 | ||
500 | |a CommentIn: Transpl Int. 2021 Nov;34(11):2001-2003. - PMID 34612545 | ||
500 | |a Citation Status MEDLINE | ||
520 | |a BACKGROUND: We compared protection of mycophenolate mofetil (MMF) and azathioprine (AZA) against acute cellular rejection (ACR) and chronic allograft nephropathy (CAN) in kidney transplant recipients on steroid-free, low-dose cyclosporine (CsA) microemulsion maintenance immunosuppression | ||
520 | |a METHODS AND FINDINGS: ATHENA, a pragmatic, prospective, multicenter trial conducted by 6 Italian transplant centers, compared the outcomes of 233 consenting recipients of a first deceased donor kidney transplant induced with low-dose thymoglobulin and basiliximab and randomized to MMF (750 mg twice/day, n = 119) or AZA (75 to 125 mg/day, n = 114) added-on maintenance low-dose CsA microemulsion and 1-week steroid. In patients without acute clinical or subclinical rejections, CsA dose was progressively halved. Primary endpoint was biopsy-proven CAN. Analysis was by intention to treat. Participants were included between June 2007 and July 2012 and followed up to August 2016. Between-group donor and recipient characteristics, donor/recipient mismatches, and follow-up CsA blood levels were similar. During a median (interquartile range (IQR)) follow-up of 47.7 (44.2 to 48.9) months, 29 of 87 biopsied patients on MMF (33.3%) versus 31 of 88 on AZA (35.2%) developed CAN (hazard ratio (HR) [95% confidence interval (CI)]: 1.147 (0.691 to 1.904, p = 0.595). Twenty and 21 patients on MMF versus 34 and 14 on AZA had clinical [HR (95% CI): 0.58 (0.34 to 1.02); p = 0.057) or biopsy-proven subclinical [HR (95% CI): 1.49 (0.76 to 2.92); p = 0.249] ACR, respectively. Combined events [HR (95% CI): 0.85 (0.56 to 1.29); p = 0.438], patient and graft survival, delayed graft function (DGF), 3-year glomerular filtration rate (GFR) [53.8 (40.6;65.7) versus 49.8 (36.8;62.5) mL/min/1.73 m2, p = 0.50], and adverse events (AEs) were not significantly different between groups. Chronicity scores other than CAN predict long-term graft outcome. Study limitations include small sample size and unblinded design | ||
520 | |a CONCLUSIONS: In this study, we found that in deceased donor kidney transplant recipients on low-dose CsA and no steroids, MMF had no significant benefits over AZA. This finding suggests that AZA, due to its lower costs, could safely replace MMF in combination with minimized immunosuppression | ||
520 | |a TRIAL REGISTRATION: ClinicalTrials.gov NCT00494741; EUDRACT 2006-005604-14 | ||
650 | 4 | |a Clinical Trial, Phase III | |
650 | 4 | |a Comparative Study | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Multicenter Study | |
650 | 4 | |a Pragmatic Clinical Trial | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Immunosuppressive Agents |2 NLM | |
650 | 7 | |a Cyclosporine |2 NLM | |
650 | 7 | |a 83HN0GTJ6D |2 NLM | |
650 | 7 | |a Mycophenolic Acid |2 NLM | |
650 | 7 | |a HU9DX48N0T |2 NLM | |
650 | 7 | |a Azathioprine |2 NLM | |
650 | 7 | |a MRK240IY2L |2 NLM | |
700 | 1 | |a Cravedi, Paolo |e verfasserin |4 aut | |
700 | 1 | |a Gotti, Eliana |e verfasserin |4 aut | |
700 | 1 | |a Plati, Annarita |e verfasserin |4 aut | |
700 | 1 | |a Marasà, Maddalena |e verfasserin |4 aut | |
700 | 1 | |a Sandrini, Silvio |e verfasserin |4 aut | |
700 | 1 | |a Bossini, Nicola |e verfasserin |4 aut | |
700 | 1 | |a Citterio, Franco |e verfasserin |4 aut | |
700 | 1 | |a Minetti, Enrico |e verfasserin |4 aut | |
700 | 1 | |a Montanaro, Domenico |e verfasserin |4 aut | |
700 | 1 | |a Sabadini, Ettore |e verfasserin |4 aut | |
700 | 1 | |a Tardanico, Regina |e verfasserin |4 aut | |
700 | 1 | |a Martinetti, Davide |e verfasserin |4 aut | |
700 | 1 | |a Gaspari, Flavio |e verfasserin |4 aut | |
700 | 1 | |a Villa, Alessandro |e verfasserin |4 aut | |
700 | 1 | |a Perna, Annalisa |e verfasserin |4 aut | |
700 | 1 | |a Peraro, Francesco |e verfasserin |4 aut | |
700 | 1 | |a Remuzzi, Giuseppe |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t PLoS medicine |d 2004 |g 18(2021), 6 vom: 25. Juni, Seite e1003668 |w (DE-627)NLM151950326 |x 1549-1676 |7 nnns |
773 | 1 | 8 | |g volume:18 |g year:2021 |g number:6 |g day:25 |g month:06 |g pages:e1003668 |
856 | 4 | 0 | |u http://dx.doi.org/10.1371/journal.pmed.1003668 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 18 |j 2021 |e 6 |b 25 |c 06 |h e1003668 |